Free Trial
NASDAQ:INGN

Inogen Q3 2025 Earnings Report

Inogen logo
$8.52 +0.15 (+1.79%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$8.52 0.00 (0.00%)
As of 10/15/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inogen EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Inogen Revenue Results

Actual Revenue
N/A
Expected Revenue
$92.20 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inogen Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Inogen Earnings Headlines

This dark force is about to change everything
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
See More Inogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inogen and other key companies, straight to your email.

About Inogen

Inogen (NASDAQ:INGN). (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen. These devices are engineered to be lightweight, battery-powered and FAA-approved for in-flight use, addressing both clinical efficacy and user convenience. The company also offers supporting accessories such as batteries, chargers and carrying cases to enhance patient experience and ensure uninterrupted oxygen delivery.

Founded in 2001 and headquartered in Goleta, California, Inogen has obtained regulatory clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval for distribution in Europe. The company serves a global customer base through direct-to-consumer sales channels as well as partnerships with home healthcare providers and distributors across North America, Europe and parts of the Asia-Pacific region. Inogen is led by President and Chief Executive Officer Scott Wilkinson, under whose leadership the company has invested in research and development to expand its product portfolio and support emerging digital health initiatives.

View Inogen Profile

More Earnings Resources from MarketBeat